What is the appropriate approach to conduct a clinical visit for a 32‑year‑old male patient with a history of substance abuse, post‑traumatic stress disorder (PTSD), oppositional defiant disorder (ODD), mood disorder, prior drug overdose, fetal alcohol spectrum disorder, smoking, and attention‑deficit/hyperactivity disorder (ADHD), presenting for a mood check and currently taking citalopram 40 mg daily, hydroxyzine 25 mg three times daily as needed for anxiety, lamotrigine 100 mg twice daily, and quetiapine 200 mg nightly?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Approach to This Mood Check Visit

For this 32-year-old male with complex psychiatric comorbidities and substance abuse history, prioritize immediate safety assessment (suicidality, substance relapse, medication adherence), followed by systematic evaluation of current mood symptoms, PTSD status, and substance use patterns, while monitoring for medication-related adverse effects—particularly QT prolongation from citalopram and metabolic effects from quetiapine.

Immediate Safety and Risk Assessment

Begin with direct assessment of:

  • Suicidal ideation, plans, or recent attempts 1. Given his history of drug overdose and current antidepressant therapy, citalopram carries FDA warnings about increased suicidal thoughts, especially with dose changes 2. Ask specifically about new or worsening suicidal thoughts, particularly if there have been any recent medication adjustments.

  • Current substance use status 1, 3. With his substance abuse history, assess:

    • Active use of alcohol, opioids, stimulants, cannabis, or other substances in the past 30 days
    • Any recent changes in use patterns or cravings
    • Whether he's using substances to self-medicate PTSD or mood symptoms 4, 5
    • Recent drug-related legal issues or risky behaviors 3

  • Aggressive or violent ideation 1. With ODD history, screen for thoughts of harming others, recent aggressive behaviors, or escalating irritability.

Structured Symptom Assessment

Mood Disorder Evaluation

Assess current depressive and manic symptoms:

  • Depression symptoms: Anhedonia, sleep changes, appetite/weight changes, concentration problems, psychomotor changes, guilt, fatigue 1
  • Manic/hypomanic symptoms: The quetiapine and lamotrigine suggest possible bipolar disorder. Screen for increased energy, decreased need for sleep, racing thoughts, reckless behavior, excessive happiness or irritability, increased talkativeness 2, 6
  • Response to current medications: Is the citalopram 40 mg (maximum dose) adequately treating depression? Any breakthrough symptoms? 2

PTSD Symptom Review

Given the high comorbidity between PTSD and substance use (25-50% dual diagnosis) 4, 5, systematically assess:

  • Re-experiencing symptoms: Intrusive memories, nightmares, flashbacks
  • Avoidance behaviors: Of trauma reminders, people, places
  • Hyperarousal: Exaggerated startle, hypervigilance, irritability, sleep disturbance
  • Negative cognitions and mood: Persistent negative beliefs, emotional numbing

The quetiapine 200 mg nightly may be addressing PTSD symptoms, particularly hyperarousal, re-experiencing, and insomnia 7, 8. Assess its effectiveness on these specific domains.

ADHD Symptom Status

With comorbid ADHD and substance abuse 9, 10:

  • Current ADHD symptoms: Inattention, hyperactivity, impulsivity affecting daily functioning
  • Whether ADHD is being treated: No stimulant medication is listed. If ADHD is untreated, this may contribute to substance use and poor treatment adherence 9
  • Impact on substance use: Untreated ADHD increases SUD severity and reduces treatment effectiveness 9

Medication-Specific Monitoring

Citalopram Safety Concerns

The FDA label mandates specific monitoring 2:

  • Cardiac symptoms: Chest pain, palpitations, syncope, dizziness (QT prolongation risk)
  • Serotonin syndrome risk: Especially with multiple serotonergic agents. Ask about agitation, confusion, muscle twitching, racing heart, sweating, fever, nausea, diarrhea, muscle rigidity
  • Bleeding risk: Unusual bruising or bleeding, particularly if using NSAIDs or aspirin
  • Hyponatremia symptoms: Headache, confusion, weakness, memory problems (higher risk in this age group with substance use)
  • Activation symptoms: New anxiety, agitation, panic attacks, insomnia, irritability, restlessness

Quetiapine Monitoring

Per FDA labeling 6:

  • Metabolic effects: Weight gain, increased appetite (measure weight, ask about recent changes)
  • Sedation: Excessive daytime sleepiness, which is the most common side effect and main reason for discontinuation 8
  • Orthostatic hypotension: Dizziness on standing
  • Extrapyramidal symptoms: Though less common with quetiapine

Lamotrigine Assessment

  • Rash: Any new skin changes (Stevens-Johnson syndrome risk)
  • Mood stabilization efficacy: Is it preventing mood episodes?
  • Adherence: Missed doses increase seizure risk if restarting

Hydroxyzine PRN Use

  • Frequency of use: How often is he needing PRN anxiety medication?
  • Effectiveness: Is 25 mg TID PRN adequate for breakthrough anxiety?
  • Sedation: Additive with quetiapine

Substance Use Detailed Assessment

Following primary care guidelines 3:

Stratify Current Use

  • Hazardous use: Any use of high-risk substances (heroin, methamphetamine, crack cocaine) 3
  • Substance abuse: Recurrent use causing role failure, legal problems, hazardous situations, interpersonal problems 3
  • Substance dependence: Tolerance, withdrawal, loss of control, continued use despite consequences 3

Specific Substances to Query

  • Alcohol: Quantity, frequency, binge drinking
  • Tobacco/nicotine: Current smoking status (documented as smoker)
  • Cannabis: Frequency and amount
  • Opioids: Including prescribed and non-prescribed
  • Stimulants: Cocaine, methamphetamine, prescription stimulants
  • Benzodiazepines: Non-prescribed use (high risk with his medications)

Readiness for Change

If active substance use is identified:

  • Assess motivation for treatment 3
  • Consider brief motivational interviewing 3
  • Determine if referral to addiction specialist is needed 3

Functional Assessment

Evaluate real-world impact:

  • Occupational functioning: Employment status, ability to maintain work
  • Social relationships: Family conflicts, isolation
  • Self-care: Hygiene, nutrition, housing stability
  • Legal issues: Pending charges, probation status
  • Treatment adherence: Pharmacy refill patterns, missed appointments

Physical Health Integration

Per APA guidelines 1:

  • Sleep quality: Beyond insomnia, assess for sleep apnea (quetiapine increases risk)
  • Cardiovascular status: Blood pressure, heart rate (citalopram QT effects)
  • Primary care engagement: Does he have a PCP? When was last physical?
  • Infectious disease screening: HIV, hepatitis C status if IV drug use history
  • Neurological symptoms: Seizure history, head injury sequelae

Family and Social History Updates

  • Family psychiatric history: Particularly suicide, substance use, bipolar disorder 1
  • Current living situation: Stability, safety, support system
  • Recent stressors: Job loss, relationship changes, legal problems, trauma re-exposure

Clinical Decision Points

If Mood Symptoms Are Inadequately Controlled

  • Citalopram is already at maximum dose (40 mg)
  • Consider whether bipolar disorder is the primary diagnosis (lamotrigine + quetiapine suggest this)
  • If unipolar depression, may need to switch antidepressants or augment
  • If bipolar depression, optimize mood stabilizers before adding/changing antidepressants

If Active Substance Use Is Present

  • Integrated treatment is essential 4, 5. Treating psychiatric disorders and SUD simultaneously improves outcomes
  • Consider whether ADHD treatment might reduce substance use 9, 10. Atomoxetine is recommended for ADHD with comorbid SUD (weak recommendation) 10
  • Assess need for addiction medicine referral or intensive outpatient program 3
  • The self-medication hypothesis suggests he may be using substances to manage untreated PTSD or ADHD symptoms 4, 5

If PTSD Symptoms Are Prominent

  • Quetiapine appears effective for PTSD, particularly hyperarousal, re-experiencing, and nightmares 7, 8
  • Current dose (200 mg) may need optimization
  • Consider trauma-focused psychotherapy referral
  • Paroxetine or venlafaxine are first-line pharmacotherapy for PTSD 7, though switching from citalopram requires careful consideration

If ADHD Is Untreated

  • This is a critical gap 9, 10. Untreated ADHD with SUD leads to worse outcomes
  • If substance use is in remission or controlled: Consider long-acting methylphenidate or atomoxetine 9, 10
  • If active substance use: Atomoxetine is preferred (non-controlled, lower abuse potential) 10
  • Simultaneous treatment of ADHD and SUD is recommended 9

Common Pitfalls to Avoid

  1. Assuming mood symptoms are only depression: With lamotrigine and quetiapine on board, consider bipolar disorder. Antidepressant monotherapy can worsen bipolar disorder.

  2. Missing active substance use: Patients may minimize use. Use non-judgmental, direct questions. Consider urine drug screen if clinical suspicion exists 3.

  3. Ignoring medication interactions: Multiple CNS depressants (quetiapine, hydroxyzine) increase sedation and fall risk. Citalopram has significant drug interactions 2.

  4. Overlooking cardiac risk: Citalopram at 40 mg has QT prolongation risk. If he has cardiac symptoms, electrolyte abnormalities, or takes other QT-prolonging drugs, obtain ECG 2.

  5. Treating disorders in isolation: The high comorbidity between PTSD, SUD, ADHD, and mood disorders requires integrated assessment and treatment 4, 5, 11.

  6. Not assessing fetal alcohol spectrum disorder impact: This may affect cognitive function, impulse control, and treatment response. Adjust expectations and interventions accordingly.

  7. Discontinuing medications abruptly: Citalopram discontinuation causes withdrawal symptoms 2. Lamotrigine discontinuation increases seizure risk.

Documentation and Follow-Up

  • Document suicide risk assessment explicitly
  • Record substance use status with specific substances and quantities
  • Note medication adherence and side effects
  • Schedule appropriate follow-up based on risk level (higher risk = sooner follow-up)
  • Consider whether more intensive level of care is needed (partial hospitalization, intensive outpatient)

References

3
Guideline

a primary care approach to substance misuse.

American family physician, 2013

8
Research

Quetiapine Treatment for Post-traumatic Stress Disorder: A Systematic Review of the Literature.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2023

Related Questions

What medication regimen adjustments are recommended for an adult patient with worsening anxiety and PTSD symptoms?
What is an appropriate treatment plan for a patient with PTSD, generalized anxiety disorder, and depression who is taking Abilify (aripiprazole) 10 mg and Seroquel (quetiapine) 50 mg and is experiencing flashback nightmares?
For a patient on a stable Suboxone (buprenorphine/naloxone) dose of 8–16 mg daily who requires ADHD treatment, can Adderall (mixed amphetamine salts) be used, and what dosing and monitoring guidelines should be followed?
What medication changes are recommended for a PTSD patient currently taking quetiapine 200 mg daily, sertraline 50 mg daily, and prazosin 2 mg nightly?
Is it safe to prescribe Adderall (amphetamine and dextroamphetamine) for a patient with ADHD and a history of substance use disorder?
How should a man with chronic diarrhea who engages in oral‑anal (fecal‑oral) sexual activity be evaluated?
I took an overdose of famotidine (H2‑receptor antagonist) and now have sharp, migrating abdominal pain; should I seek emergency medical evaluation?
I took 20 mg of famotidine (instead of 10 mg); is this an overdose and should I be concerned about my abdominal pain?
How should I manage a patient with a work‑related psychological injury who has been feeling exhausted after working two 2‑hour shifts per day for the past two weeks?
What is the appropriate treatment for spinal cord compression?
What is the recommended management for a 76-year-old postmenopausal woman with an atrophic uterus and coarse calcifications on imaging?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.